3DConsultants directors will attend the Tau Consortium Investigators' Meeting (TCIM 2024) in Denver, Colorado. The meeting will focus on accelerating the development of new treatments for Alzheimer’s disease, frontotemporal dementias, and other neurodegenerative diseases involving the dysfunctional tau protein. Tau Consortium participants act with urgency and with patients in mind to develop novel approaches and cutting-edge treatments.
Commentaires